vimarsana.com

Page 9 - ஜா ஆய்வகம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zai Lab Limited (ZLAB) Reports First Patient Treated in China in Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

Zai Lab Limited (ZLAB) Reports First Patient Treated in China in Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Zai Lab Announces First Patient Treated in China in the

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib May 28, 2021 07:30 ET | Source: Zai Lab Limited Zai Lab Limited TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics, Inc. and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan).

5 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson

5 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson Neilson’s Stake Value: $7,262,000 Percent of Kerr Neilson’s 13F Portfolio: 0.16% Number of Hedge Fund Holders: 30 Zai Lab Limited (NASDAQ: ZLAB) is a Chinese biopharmaceutical company that specialises in discovering, developing, licencing, and commercializing therapeutics for treatment of oncology, autoimmune, and infectious diseases. Early this year, the company announced its financial results for the second half and full year of 2020 in which it reported $49.0 million in total revenues for the FY 2020 compared to $13.0 million reported in the FY 2019. During the year, biopharmaceutical company’s sales of Optune amounted to $16.4 million compared to $6.4 million reported in the previous year. Zai Lab reported a net loss of $268.9 million or $3.46 per share in FY2020 compared to a net loss of $195.1 million or $3.03 per share reported in FY2019.

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape

Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.